Gilead wins US FDA OK of second triple combo HIV pill
This article was originally published in Scrip
Executive Summary
Antiviral powerhouse Gilead Sciences won the US FDA's blessing on its latest once-daily HIV medicine Complera, which combines into a single tablet its long-time marketed fixed-dose combination nucleoside reverse transcriptase inhibitor Truvada (emtricitabine and tenofovir disoproxil fumarate) with Tibotec Pharmaceuticals' non-nucleoside reverse transcriptase inhibitor (NNRTI) Edurant (rilpivirine), which was approved in the US in May (scripintelligence, 23 May 2011).